RET基因变异甲状腺癌诊疗中国专家共识(2024版)
Chinese expert consensus on the diagnosis and treatment of thyroid cancer with RET gene variations(2024 edition)
中国抗癌协会甲状腺癌专业委员会 中国抗癌协会头颈肿瘤专业委员会 中华医学会肿瘤学分会甲状腺肿瘤专业委员会 高明1
作者信息
摘要
局部晚期或转移性甲状腺癌是甲状腺癌患者死亡的重要原因.近年来,RET基因变异晚期甲状腺癌的靶向药物不断出现,然而,RET基因变异晚期甲状腺癌的精准诊疗尚不成熟,缺乏统一标准.本共识由专家组基于现有证据,结合我国临床实践经验,提出了 RET基因变异甲状腺癌的规范化诊疗流程,包括分子检测人群、检测时机、检测方法、治疗方案选择及不良反应管理等内容,以期为临床医师提供诊疗指导.
Abstract
Locally advanced or metastatic thyroid cancer is an important cause of death in thyroid cancer patients.In recent years,targeted drugs for advanced thyroid cancer with RET gene variations have been emerging.However,the precision diagnosis and treatment of RET-altered thyroid cancer remain underdeveloped in China.Based on existing evidence and clinical practice experience in China,this consensus provides standardized diagnostic and therapeutic guidelines for RET-altered thyroid cancer,including recommendations for molecular testing populations,testing timing,methodologies,treatment options,and adverse event management,aiming to provide clinical guidance for clinicians.
关键词
甲状腺肿瘤/RET基因变异/共识Key words
Thyroid neoplasms/RET gene variations/Expert consensus引用本文复制引用
出版年
2024
NETL
NSTL
万方数据